In a 322-patient MENA study, most granulomatous disease was recessively inherited

A multicentre study of 322 patients with chronic granulomatous disease across the Middle East and North Africa found that, among those with a genetic diagnosis, autosomal recessive inheritance predominated — a reversal of the pattern usually seen in Western cohorts [s1]. The finding is a window into how the region's genetics shape which rare diseases it carries, and into the diagnostic gaps that leave many patients unclassified [s1][s2].

What the disease is

Chronic granulomatous disease is an inherited immunodeficiency in which certain immune cells cannot produce the chemicals they normally use to kill bacteria and fungi, leaving patients prone to recurrent, serious infections. It can be inherited in an X-linked form, which affects mainly boys, or in autosomal recessive forms, which require a disease-causing variant from both parents.

The multicentre study, published in the Journal of Human Immunity on 7 July 2026 and led from Sultan Qaboos University Hospital in Oman, was a retrospective review of clinical features, infections, management and survival [s1].

The findings

The 322 patients had a male-to-female ratio of 1.8, and the median age was 6.0 months at disease onset but 20.0 months at diagnosis [s1]. That gap — more than a year between the first signs and a diagnosis — is itself a finding, and one the disease can ill afford, since untreated infections accumulate in the interval.

The most common infections were pneumonia in 58.0% of patients, lymphadenitis in 49.1%, skin abscesses or cellulitis in 40.7%, and invasive pulmonary aspergillosis in 17.7% [s1]. The organisms most often isolated were Staphylococcus species at 22%, Aspergillus species at 19.3%, and Pseudomonas species at 11.2% [s1].

A genetic diagnosis was established in only 108 of the 322 patients — 30.4% [s1]. Among those, inheritance was autosomal recessive in 84.3% and X-linked in 15.7% [s1]. In Western populations, X-linked disease is typically the larger share; the inversion here is what stands out [s1].

The consanguinity link

The study does not itself attribute the recessive predominance to any single cause, and the 30.4% genetic-diagnosis rate means most patients were not molecularly classified [s1]. But the pattern fits a well-documented regional feature. A separate expert-panel paper on rare diseases in the Middle East, published in the Orphanet Journal of Rare Diseases in July 2026, states that high rates of consanguinity intensify the region's rare-disease challenges, alongside sociocultural stigma, limited diagnostic capacity and inadequate infrastructure [s2].

Consanguineous marriage raises the chance that both parents carry the same recessive variant, which increases the incidence of autosomal recessive conditions. A cohort in which recessive CGD outnumbers the X-linked form four to one is consistent with that mechanism, though the study stops short of asserting it for these specific patients [s1][s2].

Survival and the system

The median survival age was 8.5 years, and the estimated 10-year survival rate was 77.3% [s1]. The authors frame CGD as a significant disease burden in the region and call for early molecular and genetic testing and access to haematopoietic stem-cell transplantation — the treatment that can be curative [s1].

The rare-disease panel paper names the structural barriers behind those recommendations: the lack of national disease registries, limited public awareness, fragmented multidisciplinary care, and restricted access to diagnostics and advanced therapies [s2]. Its top priorities were developing national registries and improving diagnostic and treatment access [s2]. A registry study like the CGD paper is, in effect, a partial answer to the first of those gaps.

The limits

Both papers have clear constraints. The CGD study is retrospective, and with a genetic diagnosis in fewer than a third of patients, the inheritance figures describe only the diagnosed subset, not the whole cohort [s1]. Survival estimates from retrospective registries can be affected by which patients are captured and followed. The rare-disease paper is an expert-panel exercise — structured opinion from 14 stakeholders, not a measurement of outcomes [s2]. What they establish together is a regional profile: a heavy recessive-disease burden, diagnosed late and incompletely, in health systems still building the registries and testing capacity to catch it [s1][s2].